Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Core Insights - Marker Therapeutics, Inc. announced that Baylor College of Medicine's TACTOPS clinical study in pancreatic cancer was featured on Good Morning America, highlighting the need for innovative approaches in treating one of the deadliest forms of cancer [1][2] Group 1: Clinical Study Highlights - The Baylor-led research published in Nature Medicine evaluated autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma (PDAC), addressing a significant unmet need in pancreatic cancer [2] - The Phase 1/2 pancreatic cancer study demonstrated a favorable safety profile with an 84.6% disease control rate when combining Multi-Antigen Targeted T cells with frontline chemotherapy, and a median overall survival of 14.1 months [3] - Infused T cells were detected up to 12 months post-treatment, with higher frequencies observed in patients who responded positively [3] Group 2: Future Developments - Marker Therapeutics plans to initiate a Company-sponsored study to potentially improve upon the Baylor study results by increasing the target antigen profile and using higher cell doses [4] - The upcoming pancreatic cancer program is expected to begin in the first half of 2026, supported by funding from the NIH Small Business Innovation Research program and the Cancer Prevention and Research Institute of Texas [4] Group 3: Technology Overview - The MAR-T cell platform is a novel, non-genetically modified cell therapy that selectively expands tumor-specific T cells capable of recognizing a broad range of tumor antigens, reducing the possibility of tumor escape [5] - The lead product, MT-601, targets six different tumor antigens and is currently being investigated in the Phase 1 APOLLO trial for lymphoma, with potential applications in pancreatic cancer [6][8]